Clinical trials: AML
AML
High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)
This is a multicenter open-label phase II trial of high dose imatinib mesylate in patients with AML in first or second relapse, or with refractory disease.
- Trial name
- NCT00707408
- Testing
- Imatinib
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Nantes University Hospital
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML)
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are…
- Conditions
- Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia(JMML)
- Trial name
- NCT00186823
- Testing
- Miltenyi Biotec CliniMACS, Stem Cell Transplantation, TBI, systemic chemotherapy and antibodies as follows:
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- St. Jude Children's Research Hospital
AML
Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML
Background The effects of granulocyte colony-stimulating factors (G-CSF) on recovery following induction chemotherapy are widely accepted. However, their impact on response and survival has not been clarified yet.
- Trial name
- TLG-AML-95-002 (NCT00820976)
- Testing
- G-CSF
- Volunteers
- 260 people
- Sponsor
- Turkish Leukemia Study Group
AML, MDS
Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)
The purpose of this study is to evaluate the OS, RFS, and TRM after HCT with low-dose total body irradiation, fludarabine, and busulfan conditioning.
- Conditions
- AML, MDS, ALL, CML
- Trial name
- NCT00815568
- Testing
- fludarabine phosphate, busulfan
- Where
- South Korea
- Volunteers
- 114 people
- Sponsor
- Samsung Medical Center
AML, Elderly Patients
Treatment Outcome in Elderly Patients
A multicenter randomized trial evaluating the possible benefit of androgens during post remission therapy in an attempt to improve the outcome of AML in older patients.All patients received the ICL regimen as induction and were…
- Trial name
- NCT00700544
- Testing
- chemotherapy treatment (see arm) + norethandrolone, chemotherapy treatment (see arms)
- Where
- France
- Volunteers
- 330 people
- Sponsor
- University Hospital, Grenoble
AML, Elderly
DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML
Overall results in the treatment of middle aged adults acute myelogenous leukemia (AML) are substantially improved in the last decade, with complete remission (CR) rates established to values of 70 to 80per cent and also…
- Trial name
- NCT00589082
- Testing
- DaunoXome, Daunorubicine
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
De Novo Akute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML)
Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T
This randomized phase II/III trial investigates the antileukemic activity and toxicity of the FLAG-Ida regimen as a second induction course in patients with acute myeloid leukaemia and bad response to the first induction cycle…
- Conditions
- De Novo Akute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Refractory Anemia With Excess of Blasts in Transformation
- Trial name
- NCT00209833
- Testing
- Cytarabine, Idarubicin, Etoposide
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Hannover Medical School